Zydus receives final approval from the USFDA for Nateglinide Tablets USP

Ahmedabad, 11 July 2016

Zydus Cadila has received the final approval from the USFDA to market Nateglinide Tablets USP in strengths of 60 mg and 120 mg.

The drug is an oral anti-diabetic agent used in the management of Type 2 diabetes mellitus and will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 100 approvals and has so far filed nearly 270 ANDAs since the commencement of the filing process in FY 2003-04.

***